Groundbreaking new research emanating from the Seaver Autism Center for Research and Treatment at Mount Sinai suggests that Phelan-McDermid syndrome (PMS), previously considered exceptionally rare, may affect a significantly larger portion of the global population than scientific community and healthcare providers had previously understood. The comprehensive findings, meticulously detailed in the journal Autism Research, now position the estimated prevalence of this complex neurodevelopmental condition at approximately 1 in 7,300 individuals, a dramatic upward revision from prior assessments. This re-evaluation holds profound implications for diagnostic strategies, therapeutic development, and the support systems essential for affected families worldwide.
Phelan-McDermid syndrome is a multisystem genetic disorder rooted in chromosomal abnormalities, specifically involving a microdeletion or a pathogenic variant within the SHANK3 gene located on the long arm of chromosome 22 (22q13.3 deletion syndrome). The SHANK3 gene plays a critical role in the formation and function of synapses—the crucial junctions between neurons that facilitate communication within the brain. Its proper functioning is fundamental for cognitive development, learning, and memory. Consequently, disruptions to this gene can precipitate a broad spectrum of developmental challenges, including significant intellectual disability, expressive language deficits, hypotonia (low muscle tone), motor delays, and a range of behavioral difficulties, often encompassing features characteristic of autism spectrum disorder. Indeed, a substantial majority of individuals diagnosed with PMS also meet the diagnostic criteria for autism, and SHANK3 alterations are recognized as contributing to up to one percent of all autism spectrum disorder cases.
Historically, accurate prevalence figures for rare genetic conditions like PMS have been notoriously difficult to establish, often relying on passive reporting or smaller, localized studies. This has frequently led to an underestimation of their true burden. The research team at Mount Sinai sought to overcome these limitations by adopting an ambitious, multi-faceted approach to data collection. Their methodology involved consolidating genetic information from an expansive cohort of nearly 180,000 individuals diagnosed with autism who had undergone various forms of genetic testing. This unprecedented scale allowed for a much more robust statistical analysis, moving beyond anecdotal evidence or limited sample sizes.
To achieve this comprehensive overview, the Mount Sinai investigators collaborated with a diverse array of institutions, integrating genetic data from ten distinct sources. These included prominent commercial genetic testing laboratories such as GeneDx, Labcorp, and Ambry Genetics, which process vast numbers of clinical samples annually. Additionally, they incorporated data from large-scale academic research initiatives, including the SPARK research study – one of the largest autism research cohorts globally – and the Autism Sequencing Consortium, a collaborative effort focused on identifying genetic causes of autism. Contributions from several major children’s hospitals further enriched the dataset, providing a broad clinical perspective. This amalgamation of data from both diagnostic and research settings offered a unique and powerful lens through which to re-evaluate the syndrome’s prevalence.
Crucially, the researchers did not simply tally confirmed diagnoses. They applied sophisticated statistical models to account for several factors that could lead to an undercount. These adjustments included estimating the proportion of undiagnosed cases within the broader population, acknowledging limitations inherent in certain types of genetic testing that might miss specific SHANK3 alterations, and factoring in individuals with Phelan-McDermid syndrome who may not exhibit features severe enough to meet the formal criteria for autism spectrum disorder, thus potentially remaining outside autism-focused genetic screening programs. After applying these rigorous correction factors, the team arrived at a revised prevalence estimate of 13.7 cases per 100,000 people, which translates directly to approximately 1 in 7,300 individuals. This represents a monumental shift from previous, considerably lower estimates, suggesting that over 45,000 people in the United States alone could be living with Phelan-McDermid syndrome, many of whom are likely undiagnosed.
The significant discrepancy between known diagnoses and this newly estimated prevalence underscores critical barriers within the current healthcare landscape. As Tess Levy, MSc, Assistant Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai, a certified genetic counselor at the Seaver Autism Center, and the lead author of the paper, highlighted, "The substantial gap between identified and estimated cases is largely attributable to the fact that many individuals presenting with developmental disabilities and autism are never offered genetic testing. Furthermore, families frequently encounter formidable insurance hurdles or receive tests that lack the specificity to adequately evaluate the SHANK3 gene." This statement emphasizes systemic challenges, from a lack of universal screening protocols to financial and access limitations, all contributing to a hidden population of individuals awaiting a definitive diagnosis.
The Mount Sinai team, therefore, strongly advocates for broader and more equitable access to genetic testing for all children diagnosed with autism or significant developmental delays. A definitive genetic diagnosis provides far more than just a name for a set of symptoms; it offers a crucial piece of the puzzle that can profoundly impact an individual’s care trajectory. Joseph D. Buxbaum, PhD, Director of the Seaver Autism Center, co-founder of the Autism Sequencing Consortium, and senior author of the paper, articulated this conviction, stating, "We recommend that every child with autism undergo genetic testing, because knowledge is power. These genetic findings empower researchers to design more targeted clinical trials for potential therapies. I truly believe that within the next five years, we’ll see successful examples of new treatments emerging from these genetic discoveries." This perspective frames genetic testing as an essential gateway to advanced therapeutic interventions and improved patient outcomes.
The publication of these findings arrives at a pivotal juncture for Phelan-McDermid syndrome research. The landscape of therapeutic development for genetic neurodevelopmental disorders is rapidly evolving, with several precision medicine approaches now advancing into clinical trials. These cutting-edge treatments are specifically designed to address the underlying biological mechanisms of the disorder, rather than merely managing symptoms. For families navigating the complexities of PMS, a genetic diagnosis now signifies much more than understanding the etiology of their loved one’s challenges. It opens doors to highly specialized medical care, participation in groundbreaking research studies, access to potentially life-changing clinical trials, connection with vital patient support networks, and, critically, the possibility of disease-modifying treatments.
This landmark study, supported by organizations like CureSHANK and Neuren Pharmaceuticals, represents one of the most exhaustive efforts to date to quantify the true prevalence of Phelan-McDermid syndrome. Rachel Groth, PhD, Head of External Innovation and Patient Advocacy at Neuren Pharmaceuticals, underscored the ethical imperative behind this research: "Neuren Pharmaceuticals initiated this landmark PMS prevalence study in collaboration with the Seaver Autism Center at Mount Sinai and CureSHANK because, with new treatments moving closer to reality, identifying these individuals has become an ethical imperative. Patients cannot benefit from these advances if they never receive a diagnosis." Her statement highlights the moral responsibility of the scientific and pharmaceutical communities to ensure that progress in the lab translates into tangible benefits for patients.
The findings resonate deeply with the experiences of families and patient advocacy groups. Geraldine Bliss, Board Chair of CureSHANK, affirmed, "This study confirms what many families, clinicians, and advocates have suspected for years. There are likely tens of thousands of individuals with Phelan-McDermid syndrome who have never received a genetic diagnosis. At a time when multiple therapeutics are advancing into clinical trials, finding these individuals has never been more important." Her words emphasize the urgency of identifying this previously hidden population, ensuring they are not left behind as therapeutic advancements accelerate.
The study’s results further reinforce CureSHANK’s dedicated efforts to expand access to comprehensive genetic testing and bolster the objectives of Start Genetic, a global awareness initiative. This campaign actively encourages patients, their families, healthcare providers, and advocacy organizations to adopt a "think genetic first" mindset when evaluating neurodevelopmental disorders. The overarching message is unequivocally clear: the transformative potential of precision medicine, with its promise of targeted and effective treatments, can only be fully realized when patients are accurately identified and diagnosed at the earliest possible stage. Without a genetic diagnosis, individuals remain in the shadows, unable to access the very interventions designed to improve their lives. This research, therefore, serves not only as a critical epidemiological update but as a clarion call for a fundamental shift in diagnostic practices for rare genetic conditions.
About the Author
